MX2022011334A - Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert. - Google Patents
Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.Info
- Publication number
- MX2022011334A MX2022011334A MX2022011334A MX2022011334A MX2022011334A MX 2022011334 A MX2022011334 A MX 2022011334A MX 2022011334 A MX2022011334 A MX 2022011334A MX 2022011334 A MX2022011334 A MX 2022011334A MX 2022011334 A MX2022011334 A MX 2022011334A
- Authority
- MX
- Mexico
- Prior art keywords
- ert
- treatment
- fabry disease
- naã
- experienced patients
- Prior art date
Links
- 208000024720 Fabry Disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000012458 free base Substances 0.000 abstract 1
- LXBIFEVIBLOUGU-DPYQTVNSSA-N migalastat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O LXBIFEVIBLOUGU-DPYQTVNSSA-N 0.000 abstract 1
- 229950007469 migalastat Drugs 0.000 abstract 1
- 210000000557 podocyte Anatomy 0.000 abstract 1
- 230000002861 ventricular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
Se proveen regímenes de dosificación para el tratamiento de la enfermedad de Fabry en un paciente. Algunos métodos se relacionan con el tratamiento de pacientes con Fabry no tratados previamente o tratados con ERT. Algunos métodos comprenden administrar al paciente aproximadamente 123 mg de equivalentes de base libre de migalastat para mejorar la masa ventricular izquierda y/o para mejorar la globotriaosilceramida en podocitos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/213,920 US9999618B2 (en) | 2007-04-26 | 2016-07-19 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011334A true MX2022011334A (es) | 2022-10-07 |
Family
ID=59416847
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018007669A MX2018007669A (es) | 2016-07-19 | 2017-07-19 | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert. |
| MX2022011334A MX2022011334A (es) | 2016-07-19 | 2018-06-20 | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018007669A MX2018007669A (es) | 2016-07-19 | 2017-07-19 | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190183869A1 (es) |
| EP (5) | EP4378524A2 (es) |
| JP (4) | JP6752270B2 (es) |
| KR (3) | KR20240017126A (es) |
| CN (1) | CN109661230A (es) |
| AR (1) | AR109103A1 (es) |
| AU (2) | AU2017298376A1 (es) |
| CA (1) | CA3031249A1 (es) |
| CL (1) | CL2018001677A1 (es) |
| CO (1) | CO2018006358A2 (es) |
| IL (1) | IL264301A (es) |
| MX (2) | MX2018007669A (es) |
| TW (2) | TW201806597A (es) |
| WO (1) | WO2018017721A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2787345T3 (en) | 2006-05-16 | 2016-05-30 | Amicus Therapeutics Inc | TREATMENT OPTIONS FOR FACTORY DISEASE |
| SI3470077T1 (sl) | 2008-02-12 | 2020-12-31 | Amicus Therapeutics, Inc. | Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem |
| US20190183869A1 (en) * | 2016-07-19 | 2019-06-20 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naïve and ert-experienced patients |
| US12020820B1 (en) * | 2017-03-03 | 2024-06-25 | Cerner Innovation, Inc. | Predicting sphingolipidoses (fabry's disease) and decision support |
| AU2018277756A1 (en) | 2017-05-30 | 2020-01-23 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| JP2021512906A (ja) * | 2018-02-06 | 2021-05-20 | アミカス セラピューティックス インコーポレイテッド | 妊娠患者におけるファブリー病の治療のためのミガラスタットの使用 |
| CA3090499A1 (en) * | 2018-02-06 | 2019-08-15 | Amicus Therapeutics, Inc. | Use of migalastat for the treatment of patients with classic fabry disease |
| US20210315875A1 (en) * | 2018-08-20 | 2021-10-14 | Amicus Therapeutics, Inc. | Methods of Treating Fabry Disease in Patients Having a Mutation in the GLA Gene |
| MX2021015352A (es) * | 2019-06-11 | 2022-04-06 | Amicus Therapeutics Inc | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal. |
| BR112022002202A2 (pt) | 2019-08-07 | 2022-06-14 | Amicus Therapeutics Inc | Métodos de tratar doença de fabry em pacientes tendo uma mutação no gene gla |
| JP2023513700A (ja) * | 2020-02-10 | 2023-04-03 | アミカス セラピューティックス インコーポレイテッド | ファブリー病の治療方法 |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
| KR102471225B1 (ko) | 2021-11-18 | 2022-11-28 | 박기용 | 어플리케이션을 통한 소비자 및 농장 연결 시스템 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| DK2787345T3 (en) * | 2006-05-16 | 2016-05-30 | Amicus Therapeutics Inc | TREATMENT OPTIONS FOR FACTORY DISEASE |
| AU2015230773B2 (en) * | 2006-05-16 | 2017-09-28 | Amicus Therapeutics Inc. | Assays for diagnosing and evaluating treatment options for fabry disease |
| WO2008121826A2 (en) | 2007-03-30 | 2008-10-09 | Amicus Therapeutics, Inc. | Method for the treatment of fabry disease using pharmacological chaperones |
| SI3470077T1 (sl) | 2008-02-12 | 2020-12-31 | Amicus Therapeutics, Inc. | Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem |
| EP3698792A1 (en) * | 2011-03-11 | 2020-08-26 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of fabry disease |
| JP2013255488A (ja) * | 2012-05-18 | 2013-12-26 | Saitama Medical Univ | 拡張期心不全非ヒトモデル動物及びその製造方法、並びに、拡張期心不全予防乃至症状改善活性を有する物質のスクリーニング方法 |
| US20190183869A1 (en) * | 2016-07-19 | 2019-06-20 | Amicus Therapeutics, Inc. | Treatment of fabry disease in ert-naïve and ert-experienced patients |
-
2016
- 2016-07-19 US US16/318,905 patent/US20190183869A1/en active Pending
-
2017
- 2017-07-19 MX MX2018007669A patent/MX2018007669A/es unknown
- 2017-07-19 EP EP24168024.8A patent/EP4378524A2/en active Pending
- 2017-07-19 JP JP2018510380A patent/JP6752270B2/ja active Active
- 2017-07-19 KR KR1020247003290A patent/KR20240017126A/ko active Search and Examination
- 2017-07-19 CA CA3031249A patent/CA3031249A1/en active Pending
- 2017-07-19 EP EP24168026.3A patent/EP4389213A2/en active Pending
- 2017-07-19 CN CN201780054621.XA patent/CN109661230A/zh active Pending
- 2017-07-19 KR KR1020197004780A patent/KR20190030729A/ko not_active IP Right Cessation
- 2017-07-19 AU AU2017298376A patent/AU2017298376A1/en not_active Abandoned
- 2017-07-19 KR KR1020237013747A patent/KR20230061563A/ko not_active Application Discontinuation
- 2017-07-19 EP EP17745612.6A patent/EP3487502A1/en active Pending
- 2017-07-19 WO PCT/US2017/042872 patent/WO2018017721A1/en active Application Filing
- 2017-07-19 EP EP23219947.1A patent/EP4356911A1/en active Pending
- 2017-07-19 EP EP23219937.2A patent/EP4324521A3/en active Pending
- 2017-07-19 TW TW106124148A patent/TW201806597A/zh unknown
- 2017-07-19 TW TW112140206A patent/TW202408513A/zh unknown
- 2017-07-19 AR ARP170102027A patent/AR109103A1/es unknown
-
2018
- 2018-06-20 MX MX2022011334A patent/MX2022011334A/es unknown
- 2018-06-20 CL CL2018001677A patent/CL2018001677A1/es unknown
- 2018-06-20 CO CONC2018/0006358A patent/CO2018006358A2/es unknown
-
2019
- 2019-01-17 IL IL264301A patent/IL264301A/en unknown
- 2019-05-22 JP JP2019096045A patent/JP2019178140A/ja not_active Withdrawn
-
2021
- 2021-11-08 JP JP2021181583A patent/JP2022033749A/ja not_active Withdrawn
-
2023
- 2023-05-18 US US18/199,120 patent/US20230321065A1/en active Pending
- 2023-07-20 AU AU2023206175A patent/AU2023206175A1/en active Pending
- 2023-11-13 JP JP2023192778A patent/JP2024026079A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109661230A (zh) | 2019-04-19 |
| AR109103A1 (es) | 2018-10-31 |
| MX2018007669A (es) | 2018-09-12 |
| AU2017298376A1 (en) | 2019-03-07 |
| CA3031249A1 (en) | 2018-01-25 |
| JP2024026079A (ja) | 2024-02-28 |
| US20190183869A1 (en) | 2019-06-20 |
| KR20240017126A (ko) | 2024-02-06 |
| EP4378524A2 (en) | 2024-06-05 |
| KR20230061563A (ko) | 2023-05-08 |
| US20230321065A1 (en) | 2023-10-12 |
| TW201806597A (zh) | 2018-03-01 |
| JP2019178140A (ja) | 2019-10-17 |
| EP4324521A2 (en) | 2024-02-21 |
| EP4324521A3 (en) | 2024-04-24 |
| AU2023206175A1 (en) | 2023-08-10 |
| WO2018017721A1 (en) | 2018-01-25 |
| JP2022033749A (ja) | 2022-03-02 |
| KR20190030729A (ko) | 2019-03-22 |
| EP4356911A1 (en) | 2024-04-24 |
| EP4389213A2 (en) | 2024-06-26 |
| JP6752270B2 (ja) | 2020-09-09 |
| TW202408513A (zh) | 2024-03-01 |
| EP3487502A1 (en) | 2019-05-29 |
| JP2018526368A (ja) | 2018-09-13 |
| IL264301A (en) | 2019-02-28 |
| CO2018006358A2 (es) | 2018-11-30 |
| CL2018001677A1 (es) | 2019-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011334A (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert. | |
| CY1124135T1 (el) | Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε | |
| MX2023005628A (es) | Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry. | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| MX2021002321A (es) | Nuevos metodos. | |
| MX2015012322A (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
| PH12017500392A1 (en) | Medical treatments based on anamorelin | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| NZ745187A (en) | 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| PH12015502655A1 (en) | Method | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
| UA95686U (uk) | Лікарський засіб для терапії захворювань передміхурової залози в формі супозиторія | |
| UA115063U (xx) | Спосіб лікування собак із больовим синдромом при панкреатиті | |
| EA201692163A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом | |
| UA104615U (uk) | Спосіб лікування токсокарозу | |
| UA95687U (uk) | Лікарський засіб для терапії захворювань передміхурової залози в формі супозиторія | |
| UA96488U (uk) | Спосіб лікування порушень гемоваскулярного гемостазу у хворих на ішемічну хворобу серця |